BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, June 30, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Merck Sharp & Dohme discloses new adenosine A2A and A2B receptor antagonists
To read the full story,
subscribe
or
sign in
.
Cancer
Merck Sharp & Dohme discloses new adenosine A2A and A2B receptor antagonists
June 27, 2024
No Comments
A Merck Sharp & Dohme LLC patent details new adenosine A2A and/or A2B receptor antagonists potentially useful for the treatment of cancer.
BioWorld Science
Cancer
Patents